ADVERTISEMENT
  About the SA Blog Network













Guest Blog

Guest Blog


Commentary invited by editors of Scientific American
Guest Blog HomeAboutContact

Trials Bolster Case for Preemptive Use of HIV Drugs to Reduce Transmission Rates

The views expressed are those of the author and are not necessarily those of Scientific American.


Email   PrintPrint



Cross-posted from Nature Medicines Spoonful of Medicine blog

Results from two trials released today provide the first evidence that taking antiretroviral drugs can prevent HIV infection among heterosexual men and women.

The preventative strategy, known as pre-exposure prophylaxis (PrEP), was first shown to be effective among gay men. But PrEP suffered a setback in April when a study testing the drug Truvada among women in Africa had to be halted prematurely owing to lack of efficacy. The new trial data, however, shows that the approach has broad potential in the quest to prevent HIV transmission, according to experts in the field.

“This is the first strong, compelling evidence that PrEP can work in this population,” said Kevin Fenton, director of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention at the US Centers for Disease Control and Prevention (CDC), during a press briefing earlier today. “It’s a major milestone.”

Continue reading on Nature Medicine‘s blog >>

Tags:






Add Comment

Add a Comment
You must sign in or register as a ScientificAmerican.com member to submit a comment.

More from Scientific American

Scientific American Back To School

Back to School Sale!

12 Digital Issues + 4 Years of Archive Access just $19.99

Order Now >

X

Email this Article



This function is currently unavailable

X